Advances and controversies in the adjuvant treatment of early breast cancer

doi:10.19401/j.cnki.1007-3639.2025.03.001

Abstract

Abstract:

Breast cancer is one of the common malignant tumors among women worldwide, and with advances in screening and diagnostic technology, more and more breast cancer patients are being diagnosed at an early stage. Adjuvant treatment options for different types of early-stage breast cancer vary. In recent years, the development of treatment strategies has focused on maximizing the efficacy of treatment while avoiding over-treatment based on the patient’s individual risk profile. For hormone receptor (HR)-positive breast cancer, the introduction of cell cyclin-dependent kinase (CDK)4/6 inhibitors has significantly improved the prognosis of intermediate- and high-risk patients. Meanwhile, chemotherapy de-escalation strategies based on genetic testing are also advancing. However, controversies remain regarding which patients can benefit from CDK4/6 inhibitor-enhanced therapy and whether premenopausal patients with intermediate-risk classification from multi-gene assays can gain benefits from chemotherapy. In human epidermal growth factor receptor 2 (HR)-positive breast cancer, anti-HER2 targeted therapies and novel antibody-drug conjugate provide more effective treatment options. However, how to screen the optimal population for dual-targeted therapy is still under exploration, and currently there is no consensus on how to select subsequent intensified regimens for patients who fail to achieve pathological complete response after neoadjuvant therapy. For triple-negative breast cancer, while traditional adjuvant therapy has been continuously optimized, the application of immunotherapy in the neoadjuvant and adjuvant phases has also made significant progress. Nevertheless, the definition of the optimal population to benefit from immunotherapy and the optimization strategy of immunotherapy are still key areas of ongoing research. This review summarized the advancements and controversies in adjuvant therapy for early breast cancer, aiming to provide references for current clinical practice and insights for future research directions.

Key words: Early breast cancer, Adjuvant treatment, Clinical research, Research progress

CLC Number:

R737.9

WANG Zhiqing, LIU Xiyu, FAN Lei. Advances and controversies in the adjuvant treatment of early breast cancer[J]. China Oncology, 2025, 35(3): 255-262.

References 46

[1]	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2]	SUN K X, ZHANG B L, LEI S Y, et al. Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022[J]. Chin Med J (Engl), 2024, 137(20): 2429-2436.
[3]	GIAQUINTO A N, SUNG H, NEWMAN L A, et al. Breast cancer statistics 2024[J]. CA A Cancer J Clinicians, 2024, 74(6): 477-495.
[4]	LOIBL S, ANDRÉ F, BACHELOT T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2024, 35(2): 159-182. doi: 10.1016/j.annonc.2023.11.016 pmid: 38101773
[5]	SHEFFIELD K M, PEACHEY J R, METHOD M, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer[J]. Future Oncol, 2022, 18(21): 2667-2682.
[6]	PAN H C, GRAY R, BRAYBROOKE J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years[J]. N Engl J Med, 2017, 377(19): 1836-1846.
[7]	RASTOGI P, O’SHAUGHNESSY J, MARTIN M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes[J]. J Clin Oncol, 2024, 42(9): 987-993.
[8]	中国抗癌协会乳腺癌专业委员会, 中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范(2024年版)[J]. 中国癌症杂志, 2023, 33(12): 1092-1187. doi: 10.19401/j.cnki.1007-3639.2023.12.004
	The Society of Breast Cancer China AntiCancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association. Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association(2024 edition)[J]. China Oncol, 2023, 33(12): 1092-1187.
[9]	GRADISHAR W J, MORAN M S, ABRAHAM J, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(5): 331-357.
[10]	FASCHING P A, STROYAKOVSKIY D, YARDLEY D, et al. LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR⁺/HER2^- early breast cancer (EBC): 4-year outcomes from the NATALEE trial[J]. Ann Oncol, 2024, 35: S1207.
[11]	HORTOBAGYI G N, LACKO A, SOHN J, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial[J]. Ann Oncol, 2025, 36(2): 149-157.
[12]	TARANTINO P, RUGO H S, CURIGLIANO G, et al. 245P Characteristics of real-world (RW) NATALEE and monarchE eligible populations: a US electronic health records (EHR) database analysis[J]. Ann Oncol, 2024, 35: S317-S318.
[13]	SPARANO J A, GRAY R J, MAKOWER D F, et al. Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial[J]. JAMA Oncol, 2020, 6(3): 367-374. doi: 10.1001/jamaoncol.2019.4794 pmid: 31566680
[14]	SPARANO J A, GRAY R J, MAKOWER D F, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med, 2018, 379(2): 111-121.
[15]	SPARANO J A. Trial assigning individualized options for treatment (TAILORx): an update including 12-year event rates[C]. San Antonio: SABCS, 2022: GS1-05
[16]	KALINSKY K, BARLOW W E, GRALOW J R, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer[J]. N Engl J Med, 2021, 385(25): 2336-2347.
[17]	KALINSKY K, BARLOW W E, PATHAK H B, et al. Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR⁺), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER)[J]. J Clin Oncol, 2024, 42(16_suppl): 505.
[18]	SUN J, MENG H, YAO L, et al. Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients[J]. Clin Cancer Res, 2017, 23(20): 6113-6119. doi: 10.1158/1078-0432.CCR-16-3227 pmid: 28724667
[19]	HU C L, HART S N, GNANAOLIVU R, et al. A population-based study of genes previously implicated in breast cancer[J]. N Engl J Med, 2021, 384(5): 440-451.
[20]	ZANG F, DING X Y, CHEN J A, et al. 627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype[J]. Breast Cancer Res Treat, 2022, 195(3): 431-439.
[21]	TUTT A N J, GARBER J E, KAUFMAN B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer[J]. N Engl J Med, 2021, 384(25): 2394-2405.
[22]	MORGANTI S, BYCHKOVSKY B L, POORVU P D, et al. Adjuvant olaparib for germline BRCA carriers with HER2^-negative early breast cancer: evidence and controversies[J]. Oncologist, 2023, 28(7): 565-574.
[23]	GARBER J. OlympiA:a phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2pathogenic variants & highrisk HER2-negative primary breast cancer: longerterm follow-up[C]. San Antonio: SABCS, 2024: GS1-09.
[24]	VON MINCKWITZ G, PROCTER M, DE AZAMBUJA E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med, 2017, 377(2): 122-131.
[25]	VON MINCKWITZ G, HUANG C S, MANO M S, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med, 2019, 380(7): 617-628.
[26]	MARTIN M, HOLMES F A, EJLERTSEN B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1688-1700. doi: S1470-2045(17)30717-9 pmid: 29146401
[27]	BURSTEIN H J, CURIGLIANO G, LOIBL S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen international consensus guidelines for the primary therapy of early breast cancer 2019[J]. Ann Oncol, 2019, 30(10): 1541-1557. doi: S0923-7534(19)60978-6 pmid: 31987446
[28]	LOIBL S, JASSEM J, SONNENBLICK A, et al. Adjuvant pertuzumab and trastuzumab in early human epidermal growth factor receptor 2-positive breast cancer in the APHINITY trial: third interim overall survival analysis with efficacy update[J]. J Clin Oncol, 2024, 42(31): 3643-3651. doi: 10.1200/JCO.23.02505 pmid: 39259927
[29]	GEYER C E JR, UNTCH M, HUANG C S, et al. Survival with trastuzumab emtansine in residual HER2-positive breast cancer[J]. N Engl J Med, 2025, 392(3): 249-257.
[30]	CHAN A, MOY B, MANSI J, et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase Ⅲ ExteNET trial[J]. Clin Breast Cancer, 2021, 21(1): 80-91.e7.
[31]	HURVITZ S A, HEGG R, CHUNG W P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial[J]. Lancet, 2023, 401(10371): 105-117.
[32]	ANDRÉ F, PARK Y H, KIM S B, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2023, 401(10390): 1773-1785.
[33]	SAURA C, MODI S, KROP I, et al. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)[J]. Ann Oncol, 2024, 35(3): 302-307.
[34]	MOON S, BAE S J, KOOK Y, et al. 233MO Ovarian function suppression in HR-positive, HER2-positive breast cancer: an exploratory analysis from the HERA trial[J]. Ann Oncol, 2024, 35: S310.
[35]	BIANCHINI G, DE ANGELIS C, LICATA L, et al. Treatment landscape of triple-negative breast cancer: expanded options, evolving needs[J]. Nat Rev Clin Oncol, 2022, 19: 91-113.
[36]	Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials[J]. Lancet, 2019, 393(10179): 1440-1452.
[37]	YU K D, YE F G, HE M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(9): 1390-1396.
[38]	WANG X, WANG S S, HUANG H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial[J]. JAMA, 2021, 325(1): 50-58.
[39]	HE M, JIANG Y Z, GONG Y, et al. Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial[J]. BMJ, 2024, 387: e079603.
[40]	GAO X Q, NAN X Y, LIU Y L, et al. Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients[J]. Hum Mutat, 2020, 41(3): 696-708.
[41]	MASUDA N, LEE S J, OHTANI S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med, 2017, 376(22): 2147-2159.
[42]	FASCHING P A, LINK T, HAUKE J, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)[J]. Ann Oncol, 2021, 32(1): 49-57. doi: 10.1016/j.annonc.2020.10.471 pmid: 33098995
[43]	CURIGLIANO G, BURSTEIN H J, GNANT M, et al. Understanding breast cancer complexity to improve patient outcomes: the St. Gallen international consensus conference for the primary therapy of individuals with early breast cancer 2023[J]. Ann Oncol, 2023, 34(11): 970-986. doi: 10.1016/j.annonc.2023.08.017 pmid: 37683978
[44]	MCARTHUR H, BAILEY A, SAJI S, et al. Adjuvant chemotherapy with or without atezolizumab for stage Ⅱ and Ⅲ triple-negative breast cancer: final analysis of the ALEXANDRA/IMpassion030 phase 3 trial[J]. Eur J Cancer, 2024, 200: 113952.
[45]	HUNTER N, HURVITZ S. Where did the passion go? -Rethinking adjuvant immune therapy for triple-negative breast cancer[J]. JAMA, 2025.
[46]	CONTE P F, DIECI M V, BISAGNI G, et al. A-BRAVE trial: A phase Ⅲ randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy[J]. J Clin Oncol, 2024, 42(17_suppl): LBA500.